Integrated Filing — IndAS



General information about company

Scrip Code 544067
NSE Symbol INNOVACAP
MSEI Symbol NOTLISTED
ISIN INE0DUT01020
Name of company INNOVA CAPTAB LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 11-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Drugs and Pharmaceutical products
Start date and time of board meeting 11-08-2026   16:07:00
End date and time of board meeting 11-08-2026   16:47:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 47,085.20 47,085.20
Other income 200.70 200.70
Total income 47,285.90 47,285.90
2 Expenses
(a) Cost of materials consumed 30,798.10 30,798.10
(b) Purchases of stock-in-trade 1,239.50 1,239.50
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,649.20) (1,649.20)
(d) Employee benefit expense 4,478.70 4,478.70
(e) Finance costs 442.90 442.90
(f) Depreciation, depletion and amortisation expense 1,171.10 1,171.10
(f) Other Expenses
1 Power and fuel 1,013.60 1,013.60
2 Freight charges 649.30 649.30
3 Packing charges 533.80 533.80
4 Stores and spares consumed 496.20 496.20
5 Repairs and maintenance 476.60 476.60
6 Rates, fees and taxes 188.70 188.70
7 House keeping expense 147.10 147.10
8 Lab consumables 133.90 133.90
9 Travelling and conveyance 305.70 305.70
10 Other Expenses 961.40 961.40
Total other expenses 4,906.30 4,906.30
Total expenses 41,387.40 41,387.40
3 Total profit before exceptional items and tax 5,898.50 5,898.50
4 Exceptional items 0.00 0.00
5 Total profit before tax 5,898.50 5,898.50
6 Tax expense
7 Current tax 1,100.30 1,100.30
8 Deferred tax 385.60 385.60
9 Total tax expenses 1,485.90 1,485.90
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 4,412.60 4,412.60
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 4,412.60 4,412.60
17 Other comprehensive income net of taxes 16.90 16.90
18 Total Comprehensive Income for the period 4,429.50 4,429.50
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 5,722.50 5,722.50
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.71 7.71
Diluted earnings (loss) per share from continuing operations 7.71 7.71
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.71 7.71
Diluted earnings (loss) per share from continuing and discontinued operations 7.71 7.71
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1 The above unaudited consolidated financial results of Innova Captab Limited the Company or the Holding Company and its subsidiaries Holding and its subsidiaries together referred to as the Group have been prepared in accordance with recognition and measurement principles laid down under Indian Accounting Standard 34 Interim Financial Reporting Ind AS 34 prescribed under Section 133 of the Companies Act 2013 the act read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 Listing Regulation as amended The results for the quarter ended 30 June 2026 are available on the Company website ie www.innovacaptab.com under investor relations section and on the stock exchange website ie www.bseindia.com and www.nseindia.com 2 The above unaudited consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 11 August 2026 The Board of Directors at their meeting held on 11 August 2026 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the unaudited consolidated financial results for the quarter ended 30 June 2026 3 The Group comprise the following entities all of which have been incorporated in India Innova Captab Limited Holding Company Univentis Medicare Limited Wholly Owned Subsidiary Company Sharon Bio Medicine Limited Step Down Subsidiary Company Univentis Foundation Subsidiary 4 The Group has only one reportable segment ie Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per SEBI LODR regulations or Listing Regulations are not applicable to the group 5 The figures of the last quarter ended 31 March 2026 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year Also the figures upto the end of the third quarter had only been reviewed and not subject to audit 6 Subsequent to the approval of the consolidated financial statements for the year ended 31 March 2026 by the Board of directors on 07 May 2026 certain inadvertent errors were identified in the consolidated financial statements including in the financial statements of the entities which form part of the group and the Company is in the process of making the necessary corrections to such financial statements prior to the adoption of such financial statements at the ensuing annual general meeting These matters do not have any material impact on the consolidated financial results for the quarter ended 30 June 2026 or on the comparative information presented therein



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) 1 The Company has only one reportable segment ie Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligation 22.60 22.60
2 Income tax relating to items that will not be reclassified to profit or loss (5.70) (5.70)
Total Amount of items that will not be reclassified to profit and loss 16.90
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 16.90 16.90